c-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts

Molecular and Cellular Biochemistry

Volumn 405, Issue 1-2, 2015, Pages 169-176

  Karimizadeh, Elham ^a   Gharibdoost, Farhad ^b   Motamed, Nasrin ^a   Jafarinejad Farsangi, Saeideh ^a   Jamshidi, Ahmadreza ^b   Mahmoudi, Mahdi ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Bax Bcl 2 ratio; c Abl; Fibroblast; Systemic sclerosis; TGF 1

Indexed keywords

ABELSON KINASE; LIPOCORTIN 5; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; APOPTOSIS; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FIBROBLAST CULTURE; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MYOFIBROBLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PUNCH BIOPSY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; CASE CONTROL STUDY; CELL DIFFERENTIATION; FIBROSIS; GENETICS; METABOLISM; MIDDLE AGED; SKIN; WOUND HEALING;

ADULT; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; MYOFIBROBLASTS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 84929945656     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2408-0     Document Type: Article

References (31)

1. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755. doi:10.1136/annrheumdis-2013-204424
2. Bhattacharyya S, Wei J, Varga J (2012) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54. doi:10.1038/nrrheum.2011.149
3. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567. doi:10.1172/jci31139
4. Darby IA, Hewitson TD (2007) Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 257:143–179. doi:10.1016/s0074-7696(07)57004-x
5. Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200:500–503. doi:10.1002/path.1427
6. Verrecchia F, Mauviel A (2007) Transforming growth factor-beta and fibrosis. World J Gastroenterol 13:3056–3062
7. Pendergast AM (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85:51–100. doi:10.1016/S0065-230X(02)85003-5
8. Wilkes MC, Leof EB (2006) Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 281:27846–27854. doi:10.1074/jbc.M603721200
9. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316. doi:10.1172/jci19603
10. Wang S, Wilkes MC, Leof EB, Hirschberg R (2005) Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19:1–11. doi:10.1096/fj.04-2370com
11. Sun X, Majumder P, Shioya H, Wu F, Kumar S, Weichselbaum R, Kharbanda S, Kufe D (2000) Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem 275:17237–17240. doi:10.1074/jbc.C000099200
12. Iqbal S, Zhang S, Driss A, Liu ZR, Kim HR, Wang Y, Ritenour C, Zhau HE, Kucuk O, Chung LW et al (2012) PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. PLoS ONE 7:e30764. doi:10.1371/journal.pone.0030764
13. Barisic K, Petrik J, Rumora L (2003) Biochemistry of apoptotic cell death. Acta Pharm 53:151–164
14. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899–1911
15. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205
16. Takashima A (2001) Establishment of fibroblast cultures. Curr Protoc Cell Biol Chapter 2:Unit 2.1. doi:10.1002/0471143030.cb0201s00
17. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108. doi:10.1038/nprot.2008.73
18. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. doi:10.1016/0003-2697(76)90527-3
19. Saile B, Matthes N, Knittel T, Ramadori G (1999) Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology 30:196–202. doi:10.1002/hep.510300144
20. Dybedal I, Guan F, Borge OJ, Veiby OP, Ramsfjell V, Nagata S, Jacobsen SE (1997) Transforming growth factor-beta1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells. Blood 90(9):3395–3403
21. Zhang HY, Phan SH (1999) Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 21:658–665. doi:10.1165/ajrcmb.21.6.3720
22. Sanchez A, Alvarez AM, Benito M, Fabregat I (1996) Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J Biol Chem 271:7416–7422. doi:10.1074/jbc.271.13.7416
23. 2. Exp Lung Res 29:123–134. doi:10.1080/01902140303773
24. Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M, Maeyama T, Hara N (2002) TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 168:6470–6478. doi:10.4049/jimmunol.168.12.6470
25. Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP (2003) Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli. FEBS Lett 541:57–63. doi:10.1016/S0014-5793(03)00299-0
26. Kumar S, Mishra N, Raina D, Saxena S, Kufe D (2003) Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol Pharmacol 63:276–282. doi:10.1124/mol.63.2.276
27. Lasfer M, Davenne L, Vadrot N, Alexia C, Sadji-Ouatas Z, Bringuier AF, Feldmann G, Pessayre D, Reyl-Desmars F (2006) Protein kinase PKC delta and c-Abl are required for mitochondrial apoptosis induction by genotoxic stress in the absence of p53, p73 and Fas receptor. FEBS Lett 580:2547–2552. doi:10.1016/j.febslet.2006.03.089
28. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311–322. doi:10.1002/art.22314
29. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, Zwerina J, Gay S, Schett G, Distler O et al (2008) Dual inhibition of c-Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22:2214–2222. doi:10.1096/fj.07-105627
30. Karimizadeh E, Motamed N, Mahmoudi M, Jafarinejad-Farsangi S, Jamshidi A, Faridani H, Gharibdoost F (2015) Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts. Arch Dermatol Res 307:135–142. doi:10.1007/s00403-014-1532-0
31. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333–340. doi:10.1046/j.0022-202x.2001.01409.x